4/19/23 Update: The U.S. Supreme Court extended the stay until Friday, April 21, 2023. Until the Court provides more clarity by then, Vermonters’ access to mifepristone remains unchanged and health care providers may continue treating their patients with mifepristone.
###
In response to the U.S. Supreme Court’s decision, issued on April 14, 2023, regarding the U.S. Department of Justice’s request for a stay in Alliance for Hippocratic Medicine, Attorney General Charity Clark issued the following statement:
“This afternoon, the U.S. Supreme Court ordered that access to mifepristone remain status quo nationwide until Wednesday, April 19. This means that, until the Court provides more clarity by then, Vermonters’ access to mifepristone remains unchanged and health care providers may continue treating their patients with mifepristone.
By Wednesday, the Court will decide what, if any, action needs to be taken during the pendency of the mifepristone challenge in a Texas district court. At that time, the Court could also choose to rule on the underlying issue, that is, whether the U.S. Food and Drug Administration’s approval of mifepristone should change.
I remain committed to doing all that I can to protect Vermonters’ access to reproductive health care.”